COMPANY PROFILE

Complix

Explore full profile

Developing a pipeline of transformative Cell Penetrating Alphabody™ (CPAB) based oncology therapeutics

Ghent, BelgiumFounded 2008Biotech & Life Sciences

Valuation $50–100M Last recorded · 2013

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Complix

Complix is a biopharmaceutical company that is developing a pipeline of transformative therapeutics. The company's focus is on creating treatments for cancer and autoimmune diseases. It has a proprietary technology platform called Alphabody™, which is used to develop these therapeutics.

The Alphabodies™ are a novel class of biopharmaceuticals that have the unique ability to cross cell membranes and act on intracellular targets, which are often difficult to reach with other types of drugs. This allows Complix to address a range of diseases that have previously been considered "undruggable." The company's pipeline includes several programs in preclinical and clinical development.

Complix is a venture-backed company and has raised funding from a syndicate of experienced life sciences investors. The company was founded in 2008 and is headquartered in Diepenbeek, Belgium.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2008
Headquarters: Ghent, Belgium
Employees: 5
Open positions: None listed
Dealroom signal: 64.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Spinout, Biotech and Pharma, Horizon Europe, DT and LS, science-based
Technology: Artificial Intelligence
Business model: Manufacturing
Client focus: b2c
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANTOther financing	Sep 2020	$1.3M	—	VLAIO- Team Bedrijfstrajecten Crossroads France-Wallonie-Vlaanderen	—
GRANT✓Other financing	Dec 2017	$550K	—	VLAIO- Team Bedrijfstrajecten Crossroads France-Wallonie-Vlaanderen	↗

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Profit	Margin
2026		—
2025		—
2024		—
2023		—
2022		—
2021		—
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Complix website traffic

Latest recorded traffic for Complix is 1.7K monthly website visits, up 794.7% over the last three months. Complix's team declined 16.7% over the past year.

Latest monthly visits1.7K 3-month web change+794.7% 1-year team growth-16.7%

Monthly website visitsDec 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
FMFoundation MedicineTransformation in cancer care, where each patient’s treatment is informed by a deep understanding of the molecular changes that contribute to their disease	Boston, United States	Acquired	1,762	$97M	$5.3B
ELEltheraBringing together experienced pharma and biotech executives with cutting-edge academic researchers to develop proprietary, first-in-class oncology drugs	Schlieren, Switzerland	Operational
EBEvaxion BiotechPioneering discovery of antigens and neo-epitopes for vaccines and antibodies using artificial intelligence	Hørsholm, Denmark	Operational
TTTOLREMO therapeuticsFocused on the discovery and development of small molecules to prevent resistance in cancer therapy	Basel, Switzerland	Operational
PEPepticomAn Artificial Intelligence (AI) company for the discovery of novel molecules in the Pharmaceutical and Agricultural markets	Jerusalem, Israel	Operational
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
EBEisbach BioInnovative start-up in biotechnology developing novel drugs that successfully target molecular vulnerabilities arising in cancer genomes	Planegg, Germany	Operational
ATAchilles TherapeuticsAchilles Tx's mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells	Stevenage, United Kingdom	Closed